206 related articles for article (PubMed ID: 35451470)
21. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike.
Zhang Y; Lu M; Mahesh KC; Kim E; Shamseldin MM; Ye C; Dravid P; Chamblee M; Park JG; Hall JM; Trivedi S; Chaiwatpongsakorn S; Kenny AD; Murthy SS; Sharma H; Liang X; Yount JS; Kapoor A; Martinez-Sobrido L; Dubey P; Boyaka PN; Peeples ME; Li J
Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2201616119. PubMed ID: 35895717
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
[TBL] [Abstract][Full Text] [Related]
23. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of a SARS-CoV-2 spike protein ectodomain subunit vaccine with a squalene emulsion adjuvant in rodents and rhesus macaques.
Solomadin M; Tabynov K; Petrovsky N; Tabynov K
Hum Vaccin Immunother; 2023 Aug; 19(2):2258571. PubMed ID: 37880990
[TBL] [Abstract][Full Text] [Related]
25. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
[TBL] [Abstract][Full Text] [Related]
26. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
27. Recombinant measles virus expressing prefusion spike protein stabilized by six rather than two prolines is more efficacious against SARS-CoV-2 infection.
Zhang Y; Lu M; Thongpan I; Xu J; Kc M; Dravid P; Trivedi S; Sharma H; Liang X; Kapoor A; Peeples ME; Li J
J Med Virol; 2023 Apr; 95(4):e28687. PubMed ID: 36941778
[TBL] [Abstract][Full Text] [Related]
28. Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.
Ávila-Nieto C; Vergara-Alert J; Amengual-Rigo P; Ainsua-Enrich E; Brustolin M; Rodríguez de la Concepción ML; Pedreño-Lopez N; Rodon J; Urrea V; Pradenas E; Marfil S; Ballana E; Riveira-Muñoz E; Pérez M; Roca N; Tarrés-Freixas F; Carabelli J; Cantero G; Pons-Grífols A; Rovirosa C; Aguilar-Gurrieri C; Ortiz R; Barajas A; Trinité B; Lepore R; Muñoz-Basagoiti J; Perez-Zsolt D; Izquierdo-Useros N; Valencia A; Blanco J; Clotet B; Guallar V; Segalés J; Carrillo J
Front Immunol; 2023; 14():1291972. PubMed ID: 38124756
[TBL] [Abstract][Full Text] [Related]
29. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2021; 12():824728. PubMed ID: 35154086
[TBL] [Abstract][Full Text] [Related]
30. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.
González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M; Mena I; McCroskery S; Coughlan L; Krammer F; García-Sastre A; Palese P; Sun W
Microbiol Spectr; 2022 Jun; 10(3):e0153822. PubMed ID: 35658571
[TBL] [Abstract][Full Text] [Related]
31. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
[TBL] [Abstract][Full Text] [Related]
32. mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2.
Darling TL; Ying B; Whitener B; VanBlargan LA; Bricker TL; Liang CY; Joshi A; Bamunuarachchi G; Seehra K; Schmitz AJ; Halfmann PJ; Kawaoka Y; Elbashir SM; Edwards DK; Thackray LB; Diamond MS; Boon ACM
Med; 2022 May; 3(5):309-324.e6. PubMed ID: 35584653
[TBL] [Abstract][Full Text] [Related]
33. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
34. Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters.
Abdelnabi R; Pérez P; Astorgano D; Albericio G; Kerstens W; Thibaut HJ; Coelmont L; Weynand B; Labiod N; Delgado R; Montenegro D; Puentes E; Rodríguez E; Neyts J; Dallmeier K; Esteban M; García-Arriaza J
Front Immunol; 2023; 14():1163159. PubMed ID: 37920464
[TBL] [Abstract][Full Text] [Related]
35. High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens.
Counoupas C; Pino P; Stella AO; Ashley C; Lukeman H; Bhattacharyya ND; Tada T; Anchisi S; Metayer C; Martinis J; Aggarwal A; Dcosta BM; Britton WJ; Kint J; Wurm MJ; Landau NR; Steain M; Turville SG; Wurm FM; David SA; Triccas JA
Microbiol Spectr; 2022 Feb; 10(1):e0169521. PubMed ID: 35171046
[TBL] [Abstract][Full Text] [Related]
36. A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern.
Ahmed S; Khan MS; Gayathri S; Singh R; Kumar S; Patel UR; Malladi SK; Rajmani RS; van Vuren PJ; Riddell S; Goldie S; Girish N; Reddy P; Upadhyaya A; Pandey S; Siddiqui S; Tyagi A; Jha S; Pandey R; Khatun O; Narayan R; Tripathi S; McAuley AJ; Singanallur NB; Vasan SS; Ringe RP; Varadarajan R
Front Immunol; 2021; 12():765211. PubMed ID: 34956193
[TBL] [Abstract][Full Text] [Related]
37. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
38. An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
Torales J; Cuenca-Torres O; Barrios L; Armoa-Garcia L; Estigarribia G; Sanabria G; Lin MY; Antonio Estrada J; Estephan L; Cheng HY; Chen C; Janssen R; Lien CE
Vaccine; 2023 Jan; 41(1):109-118. PubMed ID: 36404171
[TBL] [Abstract][Full Text] [Related]
39. MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters.
Boudewijns R; Pérez P; Lázaro-Frías A; Van Looveren D; Vercruysse T; Thibaut HJ; Weynand B; Coelmont L; Neyts J; Astorgano D; Montenegro D; Puentes E; Rodríguez E; Dallmeier K; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():845969. PubMed ID: 35371064
[TBL] [Abstract][Full Text] [Related]
40. Persistence of the Immune Responses and Cross-Neutralizing Activity With Variants of Concern Following 2 Doses of Adjuvanted SCB-2019 Coronavirus Disease 2019 Vaccine.
Richmond PC; Hatchuel L; Pacciarini F; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
J Infect Dis; 2021 Nov; 224(10):1699-1706. PubMed ID: 34480575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
